Newron Expands ENIGMA-TRS 2 Enrollment Outside U.S.
MILAN, Italy and MORRISTOWN, N.J. September 25, 2026 — Newron Pharmaceuticals announced that the U.S. clinical hold on enrollment...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MILAN, Italy and MORRISTOWN, N.J. September 25, 2026 — Newron Pharmaceuticals announced that the U.S. clinical hold on enrollment...
FOSTER CITY, Calif. — September 17, 2026 Gilead Sciences, Inc. announced a new agreement with the Pan American Health...
COPENHAGEN, Denmark, July 13, 2026 Bavarian Nordic announced that its Brazilian partner Eurofarma has submitted a marketing authorization application...
WARSAW, Poland and BUENOS AIRES, Argentina, 22 May 2026 Polpharma Biologics has entered a major licensing agreement with Tuteur...
